Haisco(SZ:002653) Xin Lang Zheng Quan·2025-10-31 23:37Core Insights - The company, Haikang, was established on August 26, 2005, and went public on January 17, 2012, on the Shenzhen Stock Exchange, focusing on the research, production, and sales of chemical pharmaceuticals, with notable performance in innovative drug development [1] Financial Performance - For Q3 2025, Haikang reported revenue of 3.3 billion yuan, ranking 21st among 110 companies in the industry, while the net profit was 295 million yuan, ranking 29th [2] - The company's revenue growth year-over-year was 19.95%, while the net profit decreased by 22.66% [6] Profitability and Debt - As of Q3 2025, Haikang's debt-to-asset ratio was 41.43%, higher than the industry average of 35.26%, indicating a need to monitor debt risks [3] - The gross profit margin was 73.90%, above the industry average of 57.17%, suggesting strong profitability potential for the company's products [3] Leadership Compensation - The chairman, Wang Junmin, received a salary of 1.7525 million yuan in 2024, a decrease of 12,900 yuan from the previous year [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 12.87% to 12,900, while the average number of shares held per shareholder decreased by 11.40% [5] Innovation and Future Prospects - The company has launched four innovative drugs that are rapidly gaining market share, with expectations for significant growth in sales [6] - Several early-stage products are progressing in clinical trials, with potential for international market entry [6]